Patterns of Inpatient Care for Newly Diagnosed Immune Thrombocytopenia in US Children’s Hospitals

OBJECTIVE: Although recent evidence-based guidelines for the management of immune thrombocytopenia (ITP) recommend a conservative, observation-based approach for the majority of patients with newly diagnosed pediatric ITP, current practice patterns are unknown. This study used the Pediatric Health Information System database to examine patterns of inpatient care in newly diagnosed ITP in freestanding US children’s hospitals and to examine geographic differences in care. METHODS: Data were extracted from Pediatric Health Information System for all newly diagnosed ITP admissions aged 1 to 18 years discharged between January 2008 and December 2010. Clinical data obtained included age, gender, length of stay, diagnoses, medications, and discharge status. RESULTS: We identified 2314 unique patients meeting the study diagnosis of newly diagnosed ITP. Noncutaneous bleeding occurred in 12% of patients (intracranial hemorrhage 0.6%), with epistaxis the most commonly reported symptom. Ninety percent of hospitalized patients received ITP-directed therapy, with intravenous immunoglobulin G the most commonly used therapy (78% of patients). We identified significant variation by geographic region in treatment strategies, length of stay, hospital charges, and likelihood of readmission. CONCLUSIONS: A substantial number of children with newly diagnosed ITP continue to be hospitalized and receive intravenous medications, although the majority of these patients do not have clinical bleeding events during the admission. By using these results as a backdrop, future studies will be able to identify if the number of ITP admissions, costs of care, and geographic variability in care decrease with the dissemination and implementation of recently published guidelines.

[1]  R. Keren,et al.  Merging of the National Cancer Institute–funded cooperative oncology group data with an administrative data source to develop a more effective platform for clinical trial analysis and comparative effectiveness research: a report from the Children's Oncology Group , 2012, Pharmacoepidemiology and drug safety.

[2]  M. Crowther,et al.  The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. , 2011, Blood.

[3]  V. Blanchette,et al.  Newly diagnosed idiopathic thrombocytopenic purpura in childhood: an observational study , 2001, The Lancet.

[4]  Ramkiran Gouripeddi,et al.  Federating clinical data from six pediatric hospitals: process and initial results from the PHIS+ Consortium. , 2011, AMIA ... Annual Symposium proceedings. AMIA Symposium.

[5]  Zhenping Chen,et al.  Health‐related quality of life measured by the Short Form 36 in immune thrombocytopenic purpura: a cross‐sectional survey in China , 2007, European journal of haematology.

[6]  P. Bolton-Maggs,et al.  Changing trends in the UK management of childhood ITP , 2011, Archives of Disease in Childhood.

[7]  H. Tamary,et al.  Newly diagnosed immune thrombocytopenia in children and adults: a comparative prospective observational registry of the Intercontinental Cooperative Immune Thrombocytopenia Study Group , 2011, Haematologica.

[8]  S. Vesely,et al.  Severe hemorrhage in children with newly diagnosed immune thrombocytopenic purpura. , 2008, Blood.

[9]  V. Blanchette,et al.  Childhood immune thrombocytopenic purpura: diagnosis and management. , 2008, Pediatric clinics of North America.

[10]  S. Jayachandran,et al.  Idiopathic thrombocytopenic purpura , 2014, Contemporary clinical dentistry.

[11]  I. Khouri,et al.  Immune Thrombocytopenic Purpura , 2018 .

[12]  E. Neufeld,et al.  Genetic studies in pediatric ITP: outlook, feasibility, and requirements , 2010, Annals of Hematology.

[13]  Drew Provan,et al.  International consensus report on the investigation and management of primary immune thrombocytopenia. , 2010, Blood.

[14]  Kenneth J. Smith,et al.  A cost‐utility analysis of treatment for acute childhood idiopathic thrombocytopenic purpura (ITP) , 2007, Pediatric blood & cancer.